GOALS: To examine the prevalence of chemotherapy-or radiotherapy-associated side effects and related treatment burden, and correlates of fatigue and missed work days among cancer patients. MATERIALS AND METHODS: A cross-sectional survey was conducted using a dual sampling frame of 63,949 cancer patients (35,751 from an online panel and 28,198 from telephone listings) > or = 18 years receiving chemotherapy and/or radiotherapy at the time of the survey or during the previous 12 months. Data were collected on cancer type, time since diagnosis, treatment side effects, visits, caregiver burden, missed work days, and sociodemographic characteristics. Data are presented only for patients receiving cancer treatment at the time of the survey. MAIN RESULTS: Of the 15,532 patients (24%) who responded to the screening questionnaire, 1,572 met the eligibility criteria and 1,569 completed the survey; 814 received chemotherapy and/or radiotherapy at the time of the survey. The most common side effects were fatigue (80%), pain (48%), and nausea/vomiting (48%). Patients spent 4.5 h, on average, per visit to treat side effects. Approximately 43% of the patients were employed; of these, 78% were actively working. Employed patients missed, on average, 18 work days annually for side effect treatment. Females, younger and unemployed patients, and those with higher levels of anxiety and depression experienced more fatigue; patients with a greater number of side effects endured more missed work days. CONCLUSIONS: In addition to the symptomatic experience of side effects, patients reported a considerable time burden for treatment. It is important to consider supportive care strategies that may effectively reduce side effects and their associated treatment burden.
GOALS: To examine the prevalence of chemotherapy-or radiotherapy-associated side effects and related treatment burden, and correlates of fatigue and missed work days among cancerpatients. MATERIALS AND METHODS: A cross-sectional survey was conducted using a dual sampling frame of 63,949 cancerpatients (35,751 from an online panel and 28,198 from telephone listings) > or = 18 years receiving chemotherapy and/or radiotherapy at the time of the survey or during the previous 12 months. Data were collected on cancer type, time since diagnosis, treatment side effects, visits, caregiver burden, missed work days, and sociodemographic characteristics. Data are presented only for patients receiving cancer treatment at the time of the survey. MAIN RESULTS: Of the 15,532 patients (24%) who responded to the screening questionnaire, 1,572 met the eligibility criteria and 1,569 completed the survey; 814 received chemotherapy and/or radiotherapy at the time of the survey. The most common side effects were fatigue (80%), pain (48%), and nausea/vomiting (48%). Patients spent 4.5 h, on average, per visit to treat side effects. Approximately 43% of the patients were employed; of these, 78% were actively working. Employed patients missed, on average, 18 work days annually for side effect treatment. Females, younger and unemployed patients, and those with higher levels of anxiety and depression experienced more fatigue; patients with a greater number of side effects endured more missed work days. CONCLUSIONS: In addition to the symptomatic experience of side effects, patients reported a considerable time burden for treatment. It is important to consider supportive care strategies that may effectively reduce side effects and their associated treatment burden.
Authors: Michael A Andrykowski; John E Schmidt; John M Salsman; Abbie O Beacham; Paul B Jacobsen Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: L E Carlson; M Angen; J Cullum; E Goodey; J Koopmans; L Lamont; J H MacRae; M Martin; G Pelletier; J Robinson; J S A Simpson; M Speca; L Tillotson; B D Bultz Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640
Authors: Amanda Digel Vandyk; Margaret B Harrison; Gail Macartney; Amanda Ross-White; Dawn Stacey Journal: Support Care Cancer Date: 2012-04-17 Impact factor: 3.603
Authors: Glenn J Lesser; Doug Case; Nancy Stark; Susan Williford; Jeff Giguere; L Astrid Garino; Michelle J Naughton; Mara Z Vitolins; Mark O Lively; Edward G Shaw Journal: J Support Oncol Date: 2013-03
Authors: Dawn Stacey; Esther Green; Barbara Ballantyne; Myriam Skrutkowski; Angela Whynot; Lucie Tardif; Joy Tarasuk; Meg Carley Journal: Support Care Cancer Date: 2015-08-15 Impact factor: 3.603
Authors: L Lee Dupuis; Cindy Milne-Wren; Marilyn Cassidy; Maru Barrera; Carol Portwine; Donna L Johnston; Mariana Pradier Silva; Cathryn Sibbald; Michael Leaker; Stacey Routh; Lillian Sung Journal: Support Care Cancer Date: 2009-06-10 Impact factor: 3.603
Authors: Ann M Berger; Kathi Mooney; Amy Alvarez-Perez; William S Breitbart; Kristen M Carpenter; David Cella; Charles Cleeland; Efrat Dotan; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Catherine Jankowski; Thomas LeBlanc; Jennifer A Ligibel; Elizabeth Trice Loggers; Belinda Mandrell; Barbara A Murphy; Oxana Palesh; William F Pirl; Steven C Plaxe; Michelle B Riba; Hope S Rugo; Carolina Salvador; Lynne I Wagner; Nina D Wagner-Johnston; Finly J Zachariah; Mary Anne Bergman; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2015-08 Impact factor: 11.908
Authors: Lis Adamsen; Morten Quist; Christina Andersen; Tom Møller; Jørn Herrstedt; Dorte Kronborg; Marie T Baadsgaard; Kirsten Vistisen; Julie Midtgaard; Birgitte Christiansen; Maria Stage; Morten T Kronborg; Mikael Rørth Journal: BMJ Date: 2009-10-13